Veterans and Servicemembers PTSD Emerging Treatment Review Act of 2026

This bill would require the Assistant Secretary of Defense for Health Affairs to send Congress's defense committees a report within 180 days of enactment. The report would review safety, dosing, and adverse event data from a 2026 clinical trial of whole psilocybin-containing mushrooms for post-traumatic stress disorder (PTSD), and how that data applies to service members, including those leaving the military. It would also describe the federal legal requirements for any expanded access to an investigational Schedule I substance, assess right-to-try options, and look at continuity of care when members move from military health care to Veterans Affairs care. The report would estimate the money, staff, infrastructure, and timeline for possible pilot programs or expanded research starting in fiscal year 2027.

Full text and official record on Congress.gov

Sponsors

• Abraham J. Hamadeh Republican sponsor
• 4 cosponsors